Background: Donepezil is an acetylcholinesterase inhibitor frequently prescribed for the treatment of mild cognitive impairment (MCI) though not approved by the Food and Drug Administration for this indication. In Alzheimer’s disease, butyrylcholinesterase (BChE) activity increases with disease progression and may replace acetylcholinesterase function. The most frequent polymorphism of BChE is the K-variant, which is associated with lower acetylcholine-hydrolyzing activity. BChE-K polymorphism has been studied in Alzheimer’s disease progression and donepezil therapy, and has led to contradictory results.
Objectives: To determine whether BChE-K genotype predicts response to donepezil in MCI.
Methods: We examined the association between BChE-K genotype and changes in cognitive function using the data collected during the ADCS vitamin E/donepezil clinical trial in MCI.
Results: We found significant interactions between BChE-K genotype and the duration of donepezil treatment, with increased changes in MMSE and CDR-SB scores compared to the common allele in MCI subjects treated during the 3-year trial. We found faster MMSE decline and CDR-SB rise in BChE-K homozygous individuals treated with donepezil compared to the untreated. We observed similar interactions between BChE-K genotype and steeper changes in MMSE and CDR-SB scores in APOE4 carriers treated with donepezil compared to controls.
Conclusion: BChE-K polymorphisms are associated with deleterious changes in cognitive decline in MCI patients treated with donepezil for 3 years. This indicates that BChE-K genotyping should be performed to help identify subsets of subjects at risk for donepezil therapy, like those carrying APOE4. BChE-K and APOE4 carriers should not be prescribed off-label donepezil therapy for MCI management.
PetersenRC, ThomasRG, GrundmanM, BennettD, DoodyR, FerrisS, GalaskoD, JinS, KayeJ, LeveyA, PfeifferE, SanoM, van DyckCH, ThalLJ, Alzheimer’sDisease Cooperative Study Group (2005) Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med352, 2379–2388.
4.
JichaGA, ParisiJE, DicksonDW, JohnsonK, ChaR, IvnikRJ, TangalosEG, BoeveBF, KnopmanDS, BraakH, PetersenRC (2006) Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol63, 674–681.
5.
CacabelosR (2007) Donepezil in Alzheimer’s disease: From conventional trials to pharmacogenetics. Neuropsychiatr Dis Treat3, 303–333.
6.
BallardCG (2002) Advances in the treatment of Alzheimer’s disease: Benefits of dual cholinesterase inhibition. Eur Neurol47, 64–70.
7.
PodolyE, ShalevDE, Shenhar-TsarfatyS, BennettER, Ben AssayagE, WilgusH, LivnahO, SoreqH (2009) The butyrylcholinesterase K variant confers structurally derived risks for Alzheimer pathology. J Biol Chem284, 17170–17179.
BizzarroA, GuglielmiV, LomastroR, ValenzaA, LauriaA, MarraC, SilveriMC, TizianoFD, BraheC, MasulloC (2010) BuChE K variant is decreased in Alzheimer’s disease not in fronto-temporal dementia. J Neural Transm (Vienna)117, 377–383.
10.
RayganiAV, ZahraiM, SoltanzadehA, DoostiM, JavadiE, PourmotabbedT (2004) Analysis of association between butyrylcholinesterase K variant and apolipoprotein E genotypes in Alzheimer’s disease. Neurosci Lett371, 142–146.
11.
ScacchiR, GambinaG, MorettoG, CorboRM (2009) Variability of AChE, BChE, and ChAT genes in the late-onset form of Alzheimer’s disease and relationships with response to treatment with donepezil and rivastigmine. Am J Med Genet B Neuropsychiatr Genet150B, 502–507.
12.
LehmannDJ, JohnstonC, SmithAD (1997) Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer’s disease. Hum Mol Genet6, 1933–1936.
13.
PanegyresPK, MamotteCD, VasikaranSD, WiltonS, FabianV, KakulasBA (1999) Butyrycholinesterase K variant and Alzheimer’s disease. J Neurol246, 369–370.
14.
GiedraitisV, KilanderL, Degerman-GunnarssonM, SundelöfJ, AxelssonT, SyvänenAC, LannfeltL, GlaserA (2009) Genetic analysis of Alzheimer’s disease in the Uppsala Longitudinal Study of Adult Men. Dement Geriatr Cogn Disord27, 59–68.
15.
BlesaR, BullockR, HeY, BergmanH, GambinaG, MeyerJ, RapatzG, NagelJ, LaneR (2006) Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer’s disease. Pharmacogenet Genomics16, 771–774.
16.
HanHJ, KwonJC, KimJE, KimSG, ParkJM, ParkKW, ParkKC, ParkKH, MoonSY, SeoSW, ChoiSH, ChoSJ (2015) Effect of rivastigmine or memantine add-on therapy is affected by butyrylcholinesterase genotype in patients with probable Alzheimer’s disease. Eur Neurol73, 23–28.
17.
MesulamMM, GuillozetA, ShawP, LeveyA, DuysenEG, LockridgeO (2002) Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. Neuroscience110, 627–639.
18.
HartmannJ, KiewertC, DuysenEG, LockridgeO, GreigNH, KleinJ (2007) Excessive hippocampal acetylcholine levels in acetylcholinesterase-deficient mice are moderated by butyrylcholinesterase activity. J Neurochem100, 1421–1429.
19.
Darreh-ShoriT, BrimijoinS, KadirA, AlmkvistO, NordbergA (2006) Differential CSF butyrylcholinesterase levels in Alzheimer’s disease patients with the ApoE epsilon4 allele, in relation to cognitive function and cerebral glucose metabolism. Neurobiol Dis24, 326–333.
20.
Darreh-ShoriT, SiaweshM, MousaviM, AndreasenN, NordbergA (2012) Apolipoprotein ɛ4 modulates phenotype of butyrylcholinesterase in CSF of patients with Alzheimer’s disease. J Alzheimers Dis28, 443–458.
